{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T16:36:17Z","timestamp":1772814977488,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","dmidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.diagmicrobio.2017.08.020","type":"journal-article","created":{"date-parts":[[2017,8,30]],"date-time":"2017-08-30T21:31:34Z","timestamp":1504128694000},"page":"328-333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of CLSI and EUCAST Cefepime breakpoint changes on the susceptibility reporting for Enterobacteriaceae"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1907-4232","authenticated-orcid":false,"given":"Jacqueline T.","family":"Bork","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily L.","family":"Heil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surbhi","family":"Leekha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randal C.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy D.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjali","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Kristie","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2017.08.020_bb0005","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","article-title":"Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas Aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.08.020_bb0010","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1128\/AAC.02252-12","article-title":"Prevalence of beta-lactamase-encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 U.S. hospitals: report from the SENTRY antimicrobial surveillance program (2010)","volume":"57","author":"Castanheira","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.08.020_bb0015","first-page":"1","article-title":"Development of a Luminex xTAG(R) assay for cost-effective multiplex deteccion of B-lactamases in gram-negative bacteria","author":"Ceyssens","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.08.020_bb0020","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1128\/AAC.05419-11","article-title":"Impact of Cefepime therapy on mortality among patients with bloodstream infections caused by extended-Spectrum-\u03b2-lactamase-producing Klebsiella pneumoniae and Escherichia coli","volume":"56","author":"Chopra","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.08.020_bb0025","series-title":"Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement. M100-S24. Vol. 32","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2014"},{"key":"10.1016\/j.diagmicrobio.2017.08.020_bb0030","doi-asserted-by":"crossref","first-page":"e0120688","DOI":"10.1371\/journal.pone.0120688","article-title":"Microbiological screening is necessary to distinguish carriers of plasmid-mediated AmpC Beta-lactamase-producing Enterobacteriaceae and extended-Spectrum Beta-lactamase (ESBL)-producing Enterobacteriaceae because of clinical similarity","volume":"10","author":"Conen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.diagmicrobio.2017.08.020_bb0035","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1517\/14656566.2016.1154538","article-title":"Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria","volume":"17","author":"D'Angelo","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.diagmicrobio.2017.08.020_bb0040","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/14737159.2017.1289087","article-title":"Recent advances in biochemical and molecular diagnostics for the rapid detection of antibiotic-resistant Enterobacteriaceae: a focus on \u00df-lactam resistance","volume":"4","author":"Decousser","year":"2017","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.diagmicrobio.2017.08.020_bb0045","series-title":"Breakpoint tables for interpretation of MICs and zone diameters","author":"EUCAST","year":"2015"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2017.08.020_bb0050","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.diagmicrobio.2013.06.015","article-title":"Rapid PCR amplification protocols decrease the turn-around time for detection of antibiotic resistance genes in gram-negative pathogens","volume":"77","author":"Geyer","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.08.020_bb0055","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1128\/JCM.03652-14","article-title":"Impact of revised cefepime CLSI breakpoints on Escherichia coli and Klebsiella pneumoniae susceptibility and potential impact if applied to pseudomonas aeruginosa","volume":"53","author":"Hamada","year":"2015","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2017.08.020_bb0060","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1128\/JCM.02424-15","article-title":"Impact of CLSI breakpoint changes on microbiology laboratories and antimicrobial stewardship programs","volume":"54","author":"Heil","year":"2016","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2017.08.020_bb0065","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/jac\/dkt136","article-title":"Consequences of revised CLSI and EUCAST guidelines for antibiotic susceptibility patterns of ESBL- and AmpC \u03b2-lactamase-producing clinical Enterobacteriaceae isolates","volume":"68","author":"Hombach","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.08.020_bb0070","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1128\/CMR.00036-08","article-title":"AmpC \u03b2-Lactamases","volume":"22","author":"Jacoby","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.diagmicrobio.2017.08.020_bb0075","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1469-0691.2007.01856.x","article-title":"Breakpoints for intravenously used cephalosporins in Enterobacteriaceae \u2013 EUCAST and CLSI breakpoints","volume":"14","author":"Kahlmeter","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2017.08.020_bb0080","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1128\/JCM.02534-10","article-title":"Comparison of polymyxin B, tigecycline, cefepime, and meropenem MICs for KPC-producing Klebsiella pneumoniae by broth microdilution, vitek 2, and etest","volume":"49","author":"Lat","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2017.08.020_bb0085","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/cid\/cis916","article-title":"Cefepime therapy for monomicrobial bacteremia caused by Cefepime-susceptible extended-Spectrum Beta-lactamase\u2013producing Enterobacteriaceae: MIC matters","volume":"56","author":"Lee","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.08.020_bb0090","doi-asserted-by":"crossref","first-page":"7558","DOI":"10.1128\/AAC.01477-15","article-title":"Cefepime therapy for monomicrobial Enterobacter cloacae bacteremia: unfavorable outcomes in patients infected by Cefepime-susceptible dose-dependent isolates","volume":"59","author":"Lee","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.08.020_bb0095","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/nrmicro1994","article-title":"The porin and the permeating antibiotic: a selective diffusion barrier in gram-negative bacteria","volume":"6","author":"Pages","year":"2008","journal-title":"Nat Rev Micro"},{"key":"10.1016\/j.diagmicrobio.2017.08.020_bb0100","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1128\/AAC.05650-11","article-title":"Clinical and microbiologic characteristics of cephalosporin-resistant Escherichia coli at three centers in the United States","volume":"56","author":"Park","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.08.020_bb0105","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3947\/ic.2017.49.1.62","article-title":"Impact of revised broad-spectrum cephalosporin clinical and laboratory standards institute breakpoints on susceptibility in Enterobacteriaceae producing AmpC Beta-lactamase","volume":"49","author":"Park","year":"2017","journal-title":"Infect Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.08.020_bb0110","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1128\/AAC.00041-14","article-title":"Unacceptably high error rates in Vitek 2 testing of cefepime susceptibility in extended-spectrum-\u03b2-lactamase-producing Escherichia coli","volume":"58","author":"Rhodes","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.08.020_bb0115","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1128\/AAC.00442-16","article-title":"Impact of cefepime susceptible-dose-dependent MIC for Enterobacteriaceae on reporting and prescribing","volume":"60","author":"Rivera","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.08.020_bb0120","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1574-6968.2002.tb11164.x","article-title":"Chromosomal ampC genes in Enterobacter species other than Enterobacter Cloacae, and ancestral association of the ACT-1 plasmid-encoded cephalosporinase to Enterobacter asburiae","volume":"210","author":"Rottman","year":"2002","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.diagmicrobio.2017.08.020_bb0125","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/cid\/ciu182","article-title":"Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia","volume":"58","author":"Siedner","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.08.020_bb0130","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/cid\/cit395","article-title":"The use of cefepime for treating AmpC Beta-lactamase-producing Enterobacteriaceae","volume":"57","author":"Tamma","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.08.020_bb0135","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/cid\/civ003","article-title":"Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum \u03b2-lactamase bacteremia","volume":"60","author":"Tamma","year":"2015","journal-title":"Clin Infect Dis"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889317302729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889317302729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T09:13:55Z","timestamp":1750842835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889317302729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0732889317302729"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.08.020","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of CLSI and EUCAST Cefepime breakpoint changes on the susceptibility reporting for Enterobacteriaceae","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}